If you put together all the new chemotherapy drugs approved over a dozen years, the average overall survival benefit is only 2.1 months. Though we often hear new cancer drugs described as “game changers” or “breakthroughs,” most afford much more modest benefits. In my last blog, I quoted an editorial in the Journal of the National Cancer Institute suggesting that the majority of new cancer drugs don’t deliver clinically meaningful benefits—at all. When they’re later proven to be ineffective, they’re pulled from the market, right? No. “[E]ven when postmarket studies show the new drugs to have n...